1 / 7

TMR’s Recent Publication includes an Extensive Analysis on the Adult Malignant Glioma Therapeutics Market

The global adult malignant glioma therapeutics market was valued at US$ 1,349.6 Mn in 2017 and is projected to expand at a CAGR of 9.2% from 2018 to 2026. The global market is anticipated to witness steady growth owing to promising effective therapies in the pipeline for addressing the gaps in treatment.<br><br>Request Sample Report @ https://bit.ly/2xTWkaB

sagarpjadhav3
Download Presentation

TMR’s Recent Publication includes an Extensive Analysis on the Adult Malignant Glioma Therapeutics Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adult Malignant Glioma Therapeutics Market Expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. ©2019 Transparency Market Research, All Rights Reserved

  2. Toxicology Testing Services Market - Snapshot Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global adult malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global adult malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026. Glioblastomamultiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval.

  3. ©2019 Transparency Market Research, All Rights Reserved

  4. Table of Content Access Full TOC

  5. Report Highlights: According to Transparency Market Research (TMR), the global adult malignant glioma therapeutics market was valued at US$ 1,349.6 Mn in 2017 and is projected to expand at a CAGR of 9.2% from 2018 to 2026. Major players operating in the global adult malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited. Request Sample of Report ©2019 Transparency Market Research, All Rights Reserved

  6. About Us Transparency Market Research (TMR) is a market intelligence company, providing North America business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. We have an experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge. Each TMR Syndicated Research report covers a different sector—such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods, and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With a wider scope and stratified research methodology, our syndicated reports strive to serve clients and satisfy their overall research requirement.

  7. To know more about us, please visit our website: www.transparencymarketresearch.com For sales queries or new topics email us on: sales@transparencymarketresearch.com For other queries contact: 90 State Street, Albany NY – 12207, United States Tel: +1-518-618-1030 T H A N K Y O U

More Related